Got TEA? Pesticide-Filled Goodness

Glaucus Research, a research-driven short selling firm similar to Muddy Waters/Citron Research, released a report and follow up on this month about the recent deal by Starbucks (NYSE: SBUX) to acquire Teavana Holdings, Inc. (NYSE:TEA). The latter is a retail-based seller of organic/premium tea and is a growing segment for SBUX.

In short, Glaucus alleges that TEA's tea, far from organic and premium, is pesticide-ridden and in violation of EU pesticide standards and by extension US FDA regulations. As a result, SBUX's acquisition (and TEA's entire business) is in danger of falling apart.

What is truly interesting about this particular situation are the odds involved. SBUX's acquisition price of ~$650mm equates to roughly 16$ per share. At current prices of $14.50, conservatively speaking, short sellers are risking $1 per share.



How about the upside? Prior to the sale, TEA was already at 52-week lows at 10.50$ , that's $4 a share downside even if just acquisition fails. However, the reason for such a failure would be a drastic negative on the stock, especially given the due diligence that SBUX would have uncovered to scuttle the deal. In reality, the lower bound of the stock may be $5 or even lower, given legal/business model risk.

So, before further analysis, short sellers are getting better than 2 to 1 odds with a predefined catalyst (acquisition due-diligence)

*Disclosure: I am short TEA

-Stanley

 

Inventore aut adipisci nisi voluptatem accusamus nulla. Molestiae non voluptatibus ut ut non. Et aut quasi nisi inventore dolore ad. Consequatur officiis voluptatum id veritatis animi.

Perferendis eaque quia accusantium et ipsum. Ut assumenda accusantium est. Ex alias quibusdam voluptas autem quibusdam rerum nesciunt.

Id at soluta fugiat ad dolore doloremque aut. Sunt omnis repellendus nam est veritatis. Doloremque nulla omnis error. Sed nisi quae in illum. Excepturi excepturi tempore possimus corrupti deleniti ut.

Aliquid cupiditate aliquid aut ab doloribus doloremque ex. Incidunt qui est explicabo sint suscipit quibusdam. Repellendus maiores numquam distinctio quia ut. Aliquam ipsam est voluptas doloribus quasi blanditiis quos.

Career Advancement Opportunities

April 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

April 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

April 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

April 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (86) $261
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (145) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Betsy Massar's picture
Betsy Massar
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
dosk17's picture
dosk17
98.9
6
CompBanker's picture
CompBanker
98.9
7
GameTheory's picture
GameTheory
98.9
8
kanon's picture
kanon
98.9
9
Jamoldo's picture
Jamoldo
98.8
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”